Skip to main content
Triangle logo TriangleGet started

Carboplatin (NCT06890338)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.: a one-minute explainerNCT068903381 min

Carboplatin trial for Epithelial Ovarian Cancer (NCT06890338). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with newly diagnosed stage III–IV high-grade serous ovarian, fallopian-tube or primary peritoneal cancer suitable for chemotherapy before surgery. At least 75% of tumor cells must show moderate-or-strong folate-receptor-alpha staining.

The idea: mirvetuximab soravtansine targets folate-receptor-alpha to deliver a cell-killing drug. It is infused with carboplatin every 21 days. Bevacizumab may be added at the investigator’s discretion. Researchers assess response before subsequent treatment, including surgery.

This phase 2 study plans 140 patients. AbbVie sponsors it, with 71 recruiting US sites. One previous carboplatin-only cycle is permitted.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.